Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Thu, Nov 21, 2024
[Archive]
Volume 38, Issue 1 (1-2024)
Med J Islam Repub Iran 2024 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Samadanifard H, Barati Z, Ghanooni A H, Eskandari D, Ziaee A, Chehrehgosha H, et al . The Impact of Empagliflozin on Inflammatory Markers in Adults with Type 2 Diabetes: A Retrospective Cohort. Med J Islam Repub Iran 2024; 38 (1) :745-750
URL: http://mjiri.iums.ac.ir/article-1-9184-en.html
URL: http://mjiri.iums.ac.ir/article-1-9184-en.html
Hossein Samadanifard 
, Zahra Barati , Amir Hossein Ghanooni , Delaram Eskandari , Amir Ziaee , Haleh Chehrehgosha , Fatemeh Sarv , Shadi Zahraei
, Zahra Barati , Amir Hossein Ghanooni , Delaram Eskandari , Amir Ziaee , Haleh Chehrehgosha , Fatemeh Sarv , Shadi Zahraei
Department of Endocrinology, Hazrat Rasoul Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran , chehrehgosha.h@iums.ac.ir
Abstract: (143 Views)
Background: Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D.
Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered P < 0.05.
Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; P = 0.025). However, the decrease in hs-CRP did not reach significance (P = 0.936).Background: Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D.
Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered P < 0.05.
Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; P = 0.025). However, the decrease in hs-CRP did not reach significance (P = 0.936). NLR did not show a significant reduction (P = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; P = 0.053). The neutrophil count did not change significantly (P = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; P = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; P < 0.001), indicating a decrease in inflammation.
Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.
NLR did not show a significant reduction (P = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; P = 0.053). The neutrophil count did not change significantly (P = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; P = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; P < 0.001), indicating a decrease in inflammation.
Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.
Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered P < 0.05.
Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; P = 0.025). However, the decrease in hs-CRP did not reach significance (P = 0.936).Background: Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D.
Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered P < 0.05.
Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; P = 0.025). However, the decrease in hs-CRP did not reach significance (P = 0.936). NLR did not show a significant reduction (P = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; P = 0.053). The neutrophil count did not change significantly (P = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; P = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; P < 0.001), indicating a decrease in inflammation.
Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.
NLR did not show a significant reduction (P = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; P = 0.053). The neutrophil count did not change significantly (P = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; P = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; P < 0.001), indicating a decrease in inflammation.
Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.
Type of Study: Original Research |
Subject:
Endocrinology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
